A Concept-to-Commercialization Viral Vector CDMO

Andelyn Biosciences is a gene therapy CDMO with deep expertise and experience in the development and production of viral vectors. With its origins including 20+ years of experience manufacturing viral vectors, Andelyn’s scientific expertise for development and characterization of gene therapies has led to GMP material being produced for over 75+ worldwide clinical trials and 400+ cGMP clinical batches. We support companies developing curative gene therapies for rare and prevalent diseases with plasmid manufacturing, process development, and GMP manufacturing capacity for both adherent and suspension processes up to 2,000L. An advanced digital model, quality system, full regulatory support, and supply chain vertical integration help accelerate the development and manufacturing of our clients' innovative therapies.

Learn More

Clinical and Commercial Manufacturing

We provide our clients with a broad range of adherent and suspension-based viral vector and vaccine manufacturing services. Our cGMP facilities offer scalability up to 2000L and the reliability of platform processes and quality systems.
LEARN MORE

Process Development

We use a set of rigorous process development guidelines for process characterization, DoE and QbD principles to establish, implement and improve our clients’ viral vector and vaccine manufacturing processes.
LEARN MORE

Viral Vector R&D Production

We manufacture research and toxicology grade viral vectors that support preclinical studies, which include pilot, proof-of-concept, dose confirmation and IND-enabling toxicology studies.
LEARN MORE

Plasmid Manufacturing

We manufacture research and toxicology grade plasmids, which support pilot, proof-of-concept, dose confirmation and IND-enabling toxicology studies. In 2022, we will be offering Phase I/IIa plasmid manufacturing services.
LEARN MORE

We support clients through all phases of development and commercialization.

Our Name

The name “Andelyn” was chosen to pay tribute to two brave young patients that participated in pivotal clinical trials that make today’s gene therapies possible.
Read Our Story

Updates from Andelyn

View All News & Media
News

March 27, 2023

Andelyn Biosciences Announce New Chief Commercial Officer

(COLUMBUS, Ohio) – Andelyn Biosciences announces the appointment of Matt Niloff as Chief Commercial Officer (CCO). Niloff will lead the...
News

March 8, 2023

Inspiring the Next Generation of Women in Life Sciences

In honor of International Women's Day, EPM brings you an exclusive roundup of inspiring commentary from over 25 empowering women in the STEM and life sciences industries. These women share their personal experiences of working in these fields, the challenges they face, and their tips for encouraging young women who are wishing to pursue a career in STEM.
News

March 1, 2023

Andelyn Biosciences Board of Directors Announce New CEO

(COLUMBUS, Ohio) – Andelyn Biosciences Chief Operations Officer Wade Macedone has been promoted to CEO of the gene and cell...
Blog

February 18, 2023

Suspension Cell Culture in Cell and Gene Therapy

The Growing Demand for Suspension Cell Culture Platforms The biopharmaceutical sector is growing and demand for viral vectors as tools...

Our Employees Fuel Our Success

Andelyn is made up of an Inspired, Innovative and Compassionate team that contribute towards a rich company culture. We are always looking for great people who want to do great things.
EXPLORE OPPORTUNITIES